Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data. Uemura K, Ito H, Jikuya R, Kondo T, et al. Int J Urol 2024;31:678-684.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Uemura K, Ito H, Jikuya R, Kondo T, et al. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data. Int J Urol 2024;31:678-684.
PMID: 38402449